Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025, which is in violation of federal securities laws [3]. Group 1: Lawsuit Details - Investors have until November 17, 2025, to file lead plaintiff applications in the lawsuit against Cytokinetics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923 [5]. Group 2: Company Disclosures - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting to review its New Drug Application for the aficamten product [4]. - On May 6, 2025, the company revealed it had held multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy [4]. Group 3: Impact on Stock Price - Following the disclosures, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5]. Group 4: Law Firm Background - Kahn Swick & Foti, LLC is a prominent boutique securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including public and private institutional investors, in seeking recoveries for investment losses due to corporate fraud [5].

Core Viewpoint - Cytokinetics is facing a class action securities lawsuit due to alleged securities fraud related to the New Drug Application (NDA) for aficamten, which misled investors about the regulatory timeline and approval process [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by false statements regarding the NDA submission and approval timeline for aficamten between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly misrepresented the expected FDA approval timeline for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS) [2]. - The revelation during a May 6, 2025 earnings call indicated that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, leading to significant losses for investors when the truth was disclosed [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and being recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging investors of Cytokinetics, Incorporated (CYTK) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking investors who may have been affected by alleged securities fraud related to Cytokinetics [1] - The announcement indicates a growing concern among investors regarding the company's practices and potential legal implications [1]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Incorporated and certain of its officers, indicating potential legal challenges for the company [1] Group 1 - The lawsuit is being handled by Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, which may suggest the seriousness of the allegations [1] - The company is listed on NASDAQ under the ticker symbol CYTK, highlighting its status as a publicly traded entity [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated, indicating potential legal matters that may affect the company [1] Company Summary - Cytokinetics, Incorporated is listed on NASDAQ under the ticker symbol CYTK [1]

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud that affected investors between December 27, 2023, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [2]. - Defendants indicated that they expected FDA approval for aficamten in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - On May 6, 2025, it was revealed during an earnings call that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Investor Information - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Company Overview - Cytokinetics, Inc. is a biopharmaceutical company focused on developing first-in-class muscle activators and next-in-class muscle inhibitors aimed at treating diseases that compromise muscle performance [1]. Group 2: Allegations and Legal Proceedings - The lawsuit claims that during the class period from December 27, 2023, to May 6, 2025, Cytokinetics made materially false statements about the expected approval timeline for aficamten's NDA, which was anticipated in the second half of 2025 based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the true situation regarding the NDA submission was revealed [2]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, and can choose to remain absent class members if they do not wish to participate [3].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated ("Cytokinetics†or the "Company†) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the "Class Period†). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. IF YOU SUF. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. ...